What it is
BPC-157 is a synthetic 15-amino-acid peptide (a pentadecapeptide) that its developers describe as a fragment of a protein found in human gastric juice; the name stands for Body Protection Compound. It was developed in Croatia by Sikiric and colleagues, and the Croatian company Pliva took it into development for inflammatory bowel disease under codes including PL 14736, PL-10 and PLD-116. Most published BPC-157 research comes from rodent experiments by that same group.
Mechanism of action
The mechanism is not settled, and most proposals come from rodent and cell experiments. The best-characterized thread is blood vessel signaling. Hsieh et al. (2017) reported that BPC-157 increased VEGFR2 expression in cultured endothelial cells without changing VEGF-A, promoted VEGFR2 internalization and activated the downstream Akt-eNOS pathway, and that rats with hind limb ischemia given the peptide recovered blood flow faster and showed more vessels. Nitric oxide signaling also appears in human tissue: in isolated human artery rings, Yildirim et al. (2026) found that BPC-157 relaxation depended largely on an intact endothelium and was weakened by the nitric oxide synthase inhibitor L-NAME. In tendon models, Staresinic et al. (2003) reported that the peptide stimulated the growth of tendon cells in culture. How the peptide reaches these targets after injection, and how long it acts, has not been characterized in humans.
What it’s most studied for
Researchers have examined BPC-157 mainly as a tissue-repair agent. The largest body of work uses rat injury models: transected or detached Achilles tendons, crushed or cut muscle, intestinal anastomoses and fistulas, and blood vessel injury. It entered research as a gut-protective peptide, which is why Pliva's early development targeted inflammatory bowel disease. More recently, sports medicine has driven interest, because the peptide is sold outside regulated channels and marketed to patients and athletes for injury recovery. Two 2026 reviews in sports medicine journals (Mendias and Awan; Tewari et al.) examined this gap between demand and evidence and concluded that controlled human trials supporting those uses are lacking.
Notable findings
Each finding carries the species or population it was observed in and the dose that study used. Doses are reported as research context, exactly as published. They are not guidance.
Achilles tendon transection in rats
Staresinic et al. (2003) cut the Achilles tendon in rats and compared BPC-157 with saline at time points up to 14 days. Treated rats showed higher load to failure, higher load to failure per area and a higher Young's modulus of elasticity than controls, along with better Achilles functional index scores. The same paper reported that the peptide stimulated tendon cell growth in culture.
- Dose studied
- 10 µg/kg, 10 ng/kg or 10 pg/kg intraperitoneally, once daily, first dose 30 minutes after surgery and last dose 24 hours before sacrifice, up to 14 days (rats)
[1] Staresinic M et al. · 2003 · PMID 14554208 ↗
Independent rat study against TB-500
Biçer et al. (2026), a group at Kocaeli University in Turkey, compared BPC-157, TB-500, both together and no treatment after surgical Achilles repair in male Sprague-Dawley rats. Maximum load to failure was higher in both peptide groups than in controls, but the difference was statistically significant only for TB-500; histology scores in the BPC-157-only group were numerically better without reaching significance. Combining the two peptides added no benefit, and the authors described the work as exploratory.
- Dose studied
- BPC-157 10 µg/kg/day intraperitoneally for four weeks after surgery (male Sprague-Dawley rats)
[2] Biçer O et al. · 2026 · PMID 42542926 ↗
Intestinal anastomosis healing in rats
Vuksic et al. (2007), from the group that developed the peptide, joined cut ends of the small intestine (ileoileal anastomosis) in rats and assessed healing macroscopically, histologically and biomechanically through day 14. The authors reported that the two higher doses improved all measured parameters of anastomotic healing compared with saline. The paper notes the compound was then in trials for inflammatory bowel disease under the Pliva codes PL-10, PLD-116 and PL 14736.
- Dose studied
- 10 µg/kg, 10 ng/kg or 10 pg/kg intraperitoneally, first dose after surgery and last dose 24 hours before sacrifice, up to 14 days; saline 5 ml/kg as control (rats)
[3] Vuksic T et al. · 2007 · PMID 17713731 ↗
Nitric oxide relaxation in human artery tissue
Yildirim et al. (2026) applied BPC-157 to rings of internal mammary artery left over from 12 elective coronary bypass operations. The peptide relaxed pre-contracted rings in a concentration-dependent way, with significantly greater relaxation when the endothelium was intact, and blocking nitric oxide synthase with L-NAME weakened the effect. No participant received the peptide, so this shows a vascular action in human tissue rather than a clinical outcome.
- Dose studied
- Increasing concentrations applied directly to isolated artery rings contracted with phenylephrine, with and without L-NAME 10⁻⁶ M (human tissue, ex vivo)
[5] Yildirim AK et al. · 2026 · PMID 42123221 ↗
Two-person intravenous safety pilot
Lee and Burgess (2025) gave intravenous BPC-157 to two adults at a private clinic in Florida, both of whom had received it before, and measured heart, liver, kidney and thyroid markers and blood glucose. The authors reported no measurable changes in these markers and no side effects. With two participants, no control group and short follow-up, the study cannot establish safety.
- Dose studied
- 10 mg intravenously over one hour on day 1, then 20 mg intravenously over one hour on day 2 (two adults)
[7] Lee E and Burgess K · 2025 · PMID 40131143 ↗
Study quality
No controlled human efficacy trials of BPC-157 have been published. The evidence comes overwhelmingly from rat injury models, and most of it from the Croatian group that developed the peptide, so independent replication is limited. One independent 2026 rat study (Biçer et al.) found weaker effects for BPC-157 than for TB-500, with the BPC-157 biomechanical gain not reaching significance. Human data consist of two small uncontrolled reports from one clinical group: a retrospective review of 16 knee-pain patients with telephone follow-up and self-reported outcomes (Lee and Padgett 2021), and a two-person intravenous safety pilot that reported no adverse effects (Lee and Burgess 2025). The human artery study (Yildirim et al. 2026) used surgical tissue, not participants. A 2026 Sports Medicine review notes that unapproved products sold outside regulated manufacturing may vary in purity, concentration and sterility, and that robust human safety data are lacking.
On the research desk
Recent records on BPC-157 from the Alpha Helix research feed, each with its evidence tier and citation.
References
- 1Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. PMID 14554208
- 2Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Joint Diseases and Related Surgery. PMID 42542926
- 3
- 4Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). PMID 27847966
- 5Endothelium-dependent nitric oxide-mediated vasorelaxant effects of BPC 157 in human internal mammary artery. Journal of Clinical Medicine. PMID 42123221
- 6Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine. PMID 34324435
- 7Safety of intravenous infusion of BPC157 in humans: a pilot study. Alternative Therapies in Health and Medicine. PMID 40131143
- 8Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. PMID 41966639
- 9Peptide supplements and their therapeutic applications in sports medicine. American Journal of Sports Medicine. PMID 42578445
Free guide
Want more than the summary?
Get our free research guide, or tell us about your practice and we’ll get back to you.